Molecular testing is transforming post-transplant care, reducing the need for invasive biopsies and personalizing medication ...

Following a meeting with the US FDA, clinical-stage biotech Dimerix has confirmed the appropriate primary endpoint for full ...

The global market for Hemodialysis and Peritoneal Dialysis has exhibited a robust growth trajectory, with its valuation increasing from $15,681.81 million in 2019 to an anticipated $22,164.86 million ...

Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do ...

Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced that it will present two posters at the American ...

Dr. Kazuyuki Numakura presented a study of primary resistance to nivolumab + ipilimumab therapy affecting second-line treatment outcomes in metastatic renal cell carcinoma (mRCC) patients. Long-term ...